BACKGROUND AND AIMS: Despite high potency, a significant proportion of patients treated with entecavir achieve only partial viral suppression. Our goal was to examine the complete viral suppression rate (undetectable HBV DNA PCR levels) with alternative therapies in such patients. METHODS: We retrospectively studied 42 consecutive patients with partial response to entecavir (detectable HBV DNA at ≥12 months of therapy) who were treated at three clinics with rescue therapies: entecavir + adefovir (n = 5), tenofovir (n = 6), and entecavir + tenofovir (n = 31). Antiviral resistance was excluded by negative mutation analysis and/or absence of virologic breakthrough (increase >1 log(10)IU/mL from nadir). RESULTS: All patients were Asian and 57 % were male with a median age of 36 (22-64) years. Only a few patients had prior exposure to lamivudine (7 %) or adefovir (7 %). Almost all patients (95 %) had positive HBeAg. Overall, the complete viral suppression rate was 79 %, and the alanine aminotransferase normalization rate was 83 % in entecavir partial responders after 6 months on rescue therapies. Cumulative complete viral suppression rates were significantly different (P = 0.0164) among the entecavir + adefovir, tenofovir, and entecavir + tenofovir treatment groups at 6 months (20 vs. 83 vs. 83 %, respectively) and 12 months (20 vs. 100 vs. 97 %). All three patients without complete viral suppression on entecavir + adefovir became aviremic 6 months after switching to entecavir + tenofovir. CONCLUSIONS: Virologic response to entecavir + tenofovir combination therapy and tenofovir monotherapy appeared to be similar in most patients, but not with the entecavir + adefovir combination.
BACKGROUND AND AIMS: Despite high potency, a significant proportion of patients treated with entecavir achieve only partial viral suppression. Our goal was to examine the complete viral suppression rate (undetectable HBV DNA PCR levels) with alternative therapies in such patients. METHODS: We retrospectively studied 42 consecutive patients with partial response to entecavir (detectable HBV DNA at ≥12 months of therapy) who were treated at three clinics with rescue therapies: entecavir + adefovir (n = 5), tenofovir (n = 6), and entecavir + tenofovir (n = 31). Antiviral resistance was excluded by negative mutation analysis and/or absence of virologic breakthrough (increase >1 log(10)IU/mL from nadir). RESULTS: All patients were Asian and 57 % were male with a median age of 36 (22-64) years. Only a few patients had prior exposure to lamivudine (7 %) or adefovir (7 %). Almost all patients (95 %) had positive HBeAg. Overall, the complete viral suppression rate was 79 %, and the alanine aminotransferase normalization rate was 83 % in entecavir partial responders after 6 months on rescue therapies. Cumulative complete viral suppression rates were significantly different (P = 0.0164) among the entecavir + adefovir, tenofovir, and entecavir + tenofovir treatment groups at 6 months (20 vs. 83 vs. 83 %, respectively) and 12 months (20 vs. 100 vs. 97 %). All three patients without complete viral suppression on entecavir + adefovir became aviremic 6 months after switching to entecavir + tenofovir. CONCLUSIONS: Virologic response to entecavir + tenofovir combination therapy and tenofovir monotherapy appeared to be similar in most patients, but not with the entecavir + adefovir combination.
Authors: Anna S Lok; Huy Trinh; Giampiero Carosi; Ulus S Akarca; Adrian Gadano; François Habersetzer; William Sievert; David Wong; Meghan Lovegren; David Cohen; Cyril Llamoso Journal: Gastroenterology Date: 2012-05-27 Impact factor: 22.682
Authors: Jurriën G P Reijnders; Katja Deterding; Jörg Petersen; Fabien Zoulim; Teresa Santantonio; Maria Buti; Florian van Bömmel; Bettina E Hansen; Heiner Wedemeyer; Harry L A Janssen Journal: J Hepatol Date: 2010-02-04 Impact factor: 25.083
Authors: Nghiem B Ha; Nghi B Ha; Ruel T Garcia; Huy N Trinh; Kevin T Chaung; Huy A Nguyen; Khanh K Nguyen; Brian S Levitt; Mindie H Nguyen Journal: Dig Dis Sci Date: 2011-02-17 Impact factor: 3.199
Authors: Carrie R Wong; Huy N Trinh; Benjamin Yip; Huy A Nguyen; Ruel T Garcia; Aijaz Ahmed; Emmet B Keeffe; Mindie H Nguyen Journal: J Clin Gastroenterol Date: 2011 Nov-Dec Impact factor: 3.062
Authors: Emmet B Keeffe; Douglas T Dieterich; Steven-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias Journal: Clin Gastroenterol Hepatol Date: 2008-08-23 Impact factor: 11.382
Authors: Roeland Zoutendijk; Jurriën G P Reijnders; Ashley Brown; Fabien Zoulim; David Mutimer; Katja Deterding; Jörg Petersen; Wolf Peter Hofmann; Maria Buti; Teresa Santantonio; Florian van Bömmel; Pierre Pradat; Ye Oo; Marc Luetgehetmann; Thomas Berg; Bettina E Hansen; Heiner Wedemeyer; Harry L A Janssen Journal: Hepatology Date: 2011-08 Impact factor: 17.425
Authors: L Lu; B Yip; H Trinh; C Q Pan; S-H B Han; C C Wong; J Li; S Chan; G Krishnan; C C Wong; M H Nguyen Journal: J Viral Hepat Date: 2014-11-24 Impact factor: 3.728
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: Jihye Park; Kyu Sik Jung; Hye Won Lee; Beom Kyung Kim; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Jun Yong Park Journal: Gut Liver Date: 2017-11-15 Impact factor: 4.519
Authors: Seung Kak Shin; Hyung Joon Yim; Jeong Han Kim; Chan Uk Lee; Jong Eun Yeon; Sang Jun Suh; Young Kul Jung; Yun Soo Kim; Ju Hyun Kim; Oh Sang Kwon Journal: Gut Liver Date: 2021-05-15 Impact factor: 4.519